Traders should anticipate significant downward pressure on share price due to extreme dilution risk; warrant overhang and low current valuation suggest high speculative risk. Monitor for insider selling or further capital raises.
Price Chart
Executive Summary
Calidi Biotherapeutics (CLDI) has closed a public offering, raising approximately $6.0 million in gross proceeds by selling over 12 million shares and accompanying warrants. The offering included three series of warrants with varying expiration terms and reset provisions, indicating significant potential future dilution.
Key Financial Metrics
Key Facts
- Closed underwritten public offering with full over-allotment exercise, raising $6.0 million in gross proceeds.
- Sold 12,094,631 shares (or pre-funded warrants) and three series of warrants (J, K, L), each exercisable for 12,094,631 shares at $0.50 per share.
- Warrants have expiration terms of 6 months (L), 1 year (K), and 5 years (J), with reset provisions on exercise price.
- Market cap is only $3M while gross proceeds are $6M, suggesting substantial dilution for existing shareholders.
- Company is on OTC exchange and in early development stage with lead candidate CLD-401 still in IND-enabling studies.
Financial Impact
Approximately $6.0 million in gross proceeds, but with potential for over 36 million additional shares upon warrant exercise, representing massive dilution relative to current market cap of $3M.
Risk Factors
- Extreme share dilution from over 36 million potential new shares from warrants.
- Low market cap ($3M) relative to offering size ($6M) increases volatility and downside risk.
- Forward-looking statements about drug development carry high uncertainty; no clinical data or revenue yet.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252397 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 8-K | $1.07 | awaiting T+20 | — | $0.6450 (+39.72%) |
Sep 22, 2026 4w ago | 8-K | $1.09 $0.7680 | ▲ +29.54% | ▲ +30.23% | $0.6450 (+40.83%) |
Sep 17, 2026 5w ago | 424B5 | $1.10 $0.8370 | ▲ +23.91% | ▲ +24.11% | $0.6450 (+41.36%) |
Aug 13, 2026 10w ago | 8-K | $1.59 $1.22 | ▼ −23.27% | ▼ −21.28% | $0.6450 (−59.43%) |
Aug 13, 2026 10w ago | Press Release | $1.59 $1.22 | ▼ −23.27% | ▼ −21.28% | $0.6450 (−59.43%) |
Jun 29, 2026 16w ago | 3 | $0.1700 $0.0933 | ▼ −45.12% | ▼ −42.80% | $0.6450 (+279.41%) |
May 26, 2026 21w ago | Press Release | $2.83 $2.51 | ▼ −11.30% | ▼ −9.24% | $0.6450 (−77.22%) |
May 22, 2026 22w ago | Press Release | $2.83 $2.51 | ▲ +11.30% | ▲ +9.24% | $0.6450 (+77.22%) |
Apr 20, 2026 27w ago | Press Release | $0.2500 $0.1830 | ▼ −26.80% | ▼ −31.00% | $0.6450 (+158.00%) |
Mar 27, 2026 30w ago | Press Release | $0.2390 $0.2240 | ▼ −6.28% | ▼ −18.87% | $0.6450 (+169.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers